To investigate the association between GLP-1 receptor agonists (GLP-1RAs) and the risk of noninfectious uveitis compared to other antihyperglycemic drugs.
Approach:
Key Findings:
GLP-1RA cohort exhibited a lower risk of uveitis compared to controls (risk ratio 0.48; 95% CI 0.46-0.51).
Subanalyses showed lower uveitis risk in patients with type 2 diabetes (RR 0.54; 95% CI 0.51-0.58) and those without diabetes (RR 0.52; 95% CI 0.46-0.59).
GLP-1RAs showed greater reductions in uveitis risk compared to metformin (RR 0.58; 95% CI 0.54-0.62) and insulin (RR 0.57; 95% CI 0.54-0.61).
GLP-1RA users had a slightly higher risk compared to those taking SGLT2 inhibitors (RR 1.17; 95% CI 1.04 to 1.32).
Interpretation:
The findings suggest potential anti-inflammatory benefits of GLP-1RAs beyond glycemic control, indicating a need for further investigation into their role in ocular inflammatory diseases.
Limitations:
Retrospective design limits causal inference.
Residual confounding remains a concern due to the observational nature of the study.
Conclusion:
GLP-1RA prescriptions were associated with a lower risk of uveitis compared to controls, warranting further investigation into their anti-inflammatory effects in ocular diseases.
